Introduction Treatment of influenza A virus infections is currently limited to few direct acting antiviral substances. Repurposing other established pharmaceuticals as antivirals could aid in improving treatment options. Methods This study investigates the antiviral properties of ProcCluster ® and procaine…
Influenza A virus (IAV) is an important respiratory pathogen that represents a significant burden on public health around the world. Seasonal outbreaks cause as many as 650 000 deaths per year. Similarly, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to public…
As vaccination efforts against SARS-CoV-2 progress in many countries, there is still an urgent need for efficient antiviral treatment strategies for those with severer disease courses, and lately, considerable efforts have been undertaken to repurpose existing drugs as antivirals. The local anaesthetic…
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease-19 (COVID-19) is still challenging healthcare systems and societies worldwide. While vaccines are available, therapeutic strategies are developing and need to be adapted to each patient. Many clinical approaches…